The latest from Spur

    [{"title":"Spur Therapeutics to Participate in Upcoming Investor Conferences","slug":"spur-therapeutics-to-participate-in-upcoming-investor-conferences","hyperlink":"https:\/\/www.globenewswire.com\/news-release\/2024\/11\/19\/2983555\/0\/en\/Spur-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences.html","date":"11.19.2024","format":"Press Release"},{"title":"Spur Therapeutics to Participate in B. Riley Securities\u2019 Next-Gen Tissue Delivery Modalities Virtual Summit","slug":"spur-therapeutics-to-participate-in-b-riley-securities-next-gen-tissue-delivery-modalities-virtual-summit","hyperlink":"https:\/\/www.globenewswire.com\/news-release\/2024\/11\/07\/2976597\/0\/en\/Spur-Therapeutics-to-Participate-in-B-Riley-Securities-Next-Gen-Tissue-Delivery-Modalities-Virtual-Summit.html","date":"11.07.2024","format":"Press Release"},{"title":"Spur Therapeutics Publishes Preclinical Proof-of-Concept Data for SBT101, its Gene Therapy Candidate in Adrenomyeloneuropathy (AMN)","slug":"spur-therapeutics-publishes-preclinical-proof-of-concept-data-for-sbt101-its-gene-therapy-candidate-in-adrenomyeloneuropathy-amn","hyperlink":"https:\/\/www.globenewswire.com\/news-release\/2024\/10\/31\/2972535\/0\/en\/Spur-Therapeutics-Publishes-Preclinical-Proof-of-Concept-Data-for-SBT101-its-Gene-Therapy-Candidate-in-Adrenomyeloneuropathy-AMN.html","date":"10.31.2024","format":"Press Release"},{"title":"Spur Therapeutics Showcases Positive New Data from Phase 1\/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease, in Oral Presentation at ESGCT 31st Annual Congress","slug":"spur-therapeutics-showcases-positive-new-data-from-phase-1-2-galileo-1-trial-of-flt201-its-novel-gene-therapy-candidate-for-gaucher-disease-in-oral-presentation-at-esgct-31st-annual-congress","hyperlink":"https:\/\/www.globenewswire.com\/news-release\/2024\/10\/23\/2967469\/0\/en\/Spur-Therapeutics-Showcases-Positive-New-Data-from-Phase-1-2-GALILEO-1-Trial-of-FLT201-Its-Novel-Gene-Therapy-Candidate-for-Gaucher-Disease-in-Oral-Presentation-at-ESGCT-31st-Annua.html","date":"10.23.2024","format":"Press Release"},{"title":"Spur\u2019s ESGCT presentation on new clinical data for FLT201 in Gaucher Disease","slug":"spurs-esgct-presentation-on-new-clinical-data-for-flt201-in-gaucher-disease","hyperlink":"https:\/\/spurtherapeutics.com\/wp-content\/uploads\/Spur-Therapeutics-ESGCT-Rome-2024-FLT201-Presentation-10-23-24.pdf","date":"10.23.2024","format":"Press Release"},{"title":"Spur Therapeutics Announces Oral Presentation Highlighting New Clinical Data for FLT201 in Gaucher Disease at Upcoming European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress","slug":"spur-therapeutics-announces-oral-presentation-highlighting-new-clinical-data-for-flt201-in-gaucher-disease-at-upcoming-european-society-of-gene-cell-therapy-esgct-31st-annual-congress","hyperlink":"https:\/\/www.globenewswire.com\/news-release\/2024\/10\/03\/2957650\/0\/en\/Spur-Therapeutics-Announces-Oral-Presentation-Highlighting-New-Clinical-Data-for-FLT201-in-Gaucher-Disease-at-Upcoming-European-Society-of-Gene-Cell-Therapy-ESGCT-31st-Annual-Congr.html","date":"10.03.2024","format":"Press Release"},{"title":"Spur Therapeutics to Participate in Chardan\u2019s 8th Annual Genetic Medicines Conference","slug":"spur-therapeutics-to-participate-in-chardans-8th-annual-genetic-medicines-conference","hyperlink":"https:\/\/www.globenewswire.com\/news-release\/2024\/09\/23\/2951332\/0\/en\/Spur-Therapeutics-to-Participate-in-Chardan-s-8th-Annual-Genetic-Medicines-Conference.html","date":"09.23.2024","format":"Press Release"},{"title":"Spur Therapeutics Completes Enrollment in Phase 1\/2 GALILEO-1 Trial of FLT201 in Gaucher Disease and Selects Dose for Planned Phase 3 Trial","slug":"spur-therapeutics-completes-enrollment-in-phase-1-2-galileo-1-trial-of-flt201-in-gaucher-disease-and-selects-dose-for-planned-phase-3-trial","hyperlink":"https:\/\/www.globenewswire.com\/news-release\/2024\/07\/08\/2909533\/0\/en\/Spur-Therapeutics-Completes-Enrollment-in-Phase-1-2-GALILEO-1-Trial-of-FLT201-in-Gaucher-Disease-and-Selects-Dose-for-Planned-Phase-3-Trial.html","date":"07.08.2024","format":"Press Release"},{"title":"Spur Therapeutics Presents Promising New Data from its GBA1 Parkinson\u2019s Disease Research Program","slug":"spur-therapeutics-presents-promising-new-data-from-its-gba1-parkinsons-disease-research-program","hyperlink":"https:\/\/www.globenewswire.com\/news-release\/2024\/07\/01\/2906591\/0\/en\/Spur-Therapeutics-Presents-Promising-New-Data-from-its-GBA1-Parkinson-s-Disease-Research-Program.html","date":"07.01.2024","format":"Press Release"},{"title":"Spur Therapeutics to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference","slug":"spur-therapeutics-to-participate-in-the-h-c-wainwright-5th-annual-neuro-perspectives-virtual-conference","hyperlink":"https:\/\/www.globenewswire.com\/news-release\/2024\/06\/20\/2901534\/0\/en\/Spur-Therapeutics-to-Participate-in-the-H-C-Wainwright-5th-Annual-Neuro-Perspectives-Virtual-Conference.html","date":"06.20.2024","format":"Press Release"},{"title":"Spur Therapeutics (Formerly Freeline) Announces New Name and Brand","slug":"spur-therapeutics-formerly-freeline-announces-new-name-and-brand","hyperlink":"https:\/\/www.globenewswire.com\/news-release\/2024\/06\/17\/2899496\/0\/en\/Spur-Therapeutics-Formerly-Freeline-Announces-New-Name-and-Brand.html","date":"06.17.2024","format":"Press Release"},{"title":"Results from GALILEO-1, a first-in-human clinical trial of FLT201 gene therapy in patients with Gaucher disease Type 1","slug":"results-from-galileo-1-a-first-in-human-clinical-trial-of-flt201-gene-therapy-in-patients-with-gaucher-disease-type-1","hyperlink":"https:\/\/spurtherapeutics.com\/wp-content\/uploads\/Freeline-GALILEO-1-Results-ASGCT2024-Final-Presentation.pdf","date":"05.09.2024","format":"Presentation"},{"title":"GBA1-Linked Parkinson\u2019s Disease AAV Gene Therapy (ASGCT 2024)","slug":"gba1-linked-parkinsons-disease-aav-gene-therapy-asgct-2024","hyperlink":"https:\/\/spurtherapeutics.com\/wp-content\/uploads\/Freeline-GBA1-PD-ASGCT2024-Final-Presentation.pdf","date":"05.09.2024","format":"Presentation"},{"title":"Results from GALILEO-1, a first-in-human clinical trial of FLT201 gene therapy in patients with Gaucher disease Type 1 (ESGCT 2023)","slug":"results-from-galileo-1-a-first-in-human-clinical-trial-of-flt201-gene-therapy-in-patients-with-gaucher-disease-type-1-esgct-2023","hyperlink":"https:\/\/spurtherapeutics.com\/wp-content\/uploads\/Freeline-GALILEO-1-Results-ASGCT2024-Final-Presentation-1.pdf","date":"10.25.2023","format":"Presentation"},{"title":"Design of GALILEO-1, a Phase 1\/2 safety and efficacy study of FLT201 in adult patients with Gaucher disease Type 1 (World Symposium 2022)","slug":"design-of-galileo-1-a-phase-1-2-safety-and-efficacy-study-of-flt201-in-adult-patients-with-gaucher-disease-type-1-world-symposium-2022","hyperlink":"https:\/\/spurtherapeutics.com\/wp-content\/uploads\/worldsymposium_2022_galileo1_hughes-et-al.pdf","date":"02.10.2022","format":"Presentation"},{"title":"FLT201, a Novel Investigational AAV-Mediated Gene Therapy Candidate for Gaucher Disease Type 1","slug":"flt201-a-novel-investigational-aav-mediated-gene-therapy-candidate-for-gaucher-disease-type-1","hyperlink":"https:\/\/player.vimeo.com\/video\/547871323","date":"05.11.2021","format":"Presentation"},{"title":"FLT201: An AAV-Mediated Gene Therapy for Type 1 Gaucher Disease Designed to Target Difficult to Reach Tissues (World Symposium 2021)","slug":"flt201-an-aav-mediated-gene-therapy-for-type-1-gaucher-disease-designed-to-target-difficult-to-reach-tissues-world-symposium-2021","hyperlink":"https:\/\/spurtherapeutics.com\/wp-content\/uploads\/flt201-an-aav-mediated-gene-therapy-for-type-1-gaucher-disease-designed.pdf","date":"02.08.2021","format":"Presentation"},{"title":"Generation of \u03b2-Glucocerebrosidase Variants with Increased Half-life in Human Plasma for Liver Directed AAV Gene Therapy for the Treatment of Type 1 Gaucher Disease (World Symposium 2021)","slug":"generation-of-%ce%b2-glucocerebrosidase-variants-with-increased-half-life-in-human-plasma-for-liver-directed-aav-gene-therapy-for-the-treatment-of-type-1-gaucher-disease-world-symposium-2021","hyperlink":"https:\/\/spurtherapeutics.com\/wp-content\/uploads\/generation-of-\u03b2-glucocerebrosidase-variants-with-increased-half-life-in-human-plasma-for.pdf","date":"02.08.2021","format":"Presentation"},{"title":"Liver directed AAV gene therapy to treat Gaucher disease (Molecular Genetics and Metabolism, 2019)","slug":"liver-directed-aav-gene-therapy-to-treat-gaucher-disease-molecular-genetics-and-metabolism-2019","hyperlink":"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S1096719218310333","date":"02.04.2019","format":"Publication"},{"title":"Explore earlier archived updates and announcements.","slug":"explore-earlier-archived-updates-and-announcements","hyperlink":"https:\/\/www.globenewswire.com\/en\/search\/keyword\/Freeline%252520Therapeutics%252520Holdings%252520plc\/tag\/freeline%252520therapeutics?pageSize=10","date":"Archive","format":"Press Release"}]  

Featured

Learn more about Spur, our mission, and our product candidates.

Download the overview deck

Filter by topic

• Press releases & company updates
• Gaucher Disease
• Parkinson’s Disease
• AMN